⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LBRX News
LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
globenewswire.com
LBRX
Form 8-K
sec.gov
LBRX
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
globenewswire.com
LBRX
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
globenewswire.com
LBRX
Form 8-K
sec.gov
LBRX
Form 8-K
sec.gov
LBRX
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
globenewswire.com
LBRX
NMRA
AMGN
ABT
LB Pharmaceuticals to Participate in Upcoming March Investor Events
globenewswire.com
LBRX
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments
prnewswire.com
GHRS
DFTX
HELP
ATAI
LBRX
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
LBRX